10X Genomics Inc (OQ:TXG)

Sector:  Healthcare Industry:  Medical Equipment, Supplies & Distribution
 
See Regulatory Filings on SEC
Company Contact
Address: 6230 Stoneridge Mall Road
PLEASANTON CA 94588
Tel: N/A
Website: https://www.10xgenomics.com
IR: See website
<
Key People
Benjamin J. Hindson
President, Co-Founder, Chief Scientific Officer, Director
Serge Wilson Saxonov
Chief Executive Officer, Co-Founder, Director
Justin J. Mcanear
Chief Financial Officer
Eric S. Whitaker
Chief Legal Officer
   
Business Overview
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for analyzing biological systems. Its Chromium platform includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, and others.
Financial Overview
For the fiscal year ended 31 December 2023, 10X Genomics Inc revenues increased 20% to $618.7M. Net loss increased 54% to $255.1M. Revenues reflect Instruments segment increase of 71% to $123.5M, Consumables segment increase of 10% to $479.6M, United States segment increase of 26% to $360.1M, Europe, the Middle East and Africa segment increase of 22% to $142.3M.
Employees: 1,259 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $2,891M as of Dec 31, 2023
Annual revenue (TTM): $618.73M as of Dec 31, 2023
EBITDA (TTM): -$227.02M as of Dec 31, 2023
Net annual income (TTM): -$255.10M as of Dec 31, 2023
Free cash flow (TTM): -$64.72M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 119,166,544 as of Jan 31, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.